{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:08:09Z","timestamp":1781712489590,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinthera.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T23:37:03Z","timestamp":1731454623000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated With Docetaxel-Based Chemotherapy: A Retrospective Analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Xueting","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhe","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.10.006_bib0001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12325-018-0841-7","article-title":"Patterns of use of docetaxel-containing adjuvant chemotherapy among Chinese patients with operable breast cancer: a multicenter observational study","volume":"36","author":"Xie","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0003","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1007\/s00520-020-05603-w","article-title":"Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00520-016-3420-y","article-title":"Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel","volume":"25","author":"Kang","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cas.12647","article-title":"Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose","volume":"106","author":"Kenmotsu","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107273","article-title":"Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis","volume":"9","author":"Yerushalmi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0007","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/ajco.12682","article-title":"Toxicity profile differences of adjuvant docetaxel\/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients","volume":"13","author":"Chow","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0008","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roche","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0009","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-015-3531-z","article-title":"The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis","volume":"153","author":"Do","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0010","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0011","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1177\/10781552211030974","article-title":"Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer","volume":"28","author":"Zekri","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0012","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-021-06387-1","article-title":"Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer","volume":"190","author":"Van Belle","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0013","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/1078155215625459","article-title":"Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review","volume":"22","author":"Mitchell","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0014","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.3747\/co.19.948","article-title":"Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience","volume":"19","author":"Zhu","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0015","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1002\/cam4.6079","article-title":"A multicenter phase II trial of primary prophylactic PEG-rhG-CSF in pediatric patients with solid tumors and non-Hodgkin lymphoma after chemotherapy: an interim analysis","volume":"12","author":"Huang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0016","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jca.21550","article-title":"Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis","volume":"32","author":"Kuan","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0017","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1078155217714859","article-title":"Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events","volume":"24","author":"Bond","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.breast.2015.11.007","article-title":"The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer\u2014further observations from the IMPACT solid study","volume":"25","author":"Maenpaa","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0019","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12967-020-02394-w","article-title":"Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study","volume":"18","author":"Sun","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J Anesthesiol"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0021","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1186\/s12885-023-11198-2","article-title":"Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients","volume":"23","author":"Jiang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0022","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1007\/s00520-020-05868-1","article-title":"Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer","volume":"29","author":"Kimura","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-010-0843-8","article-title":"Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy","volume":"19","author":"Chan","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-016-4028-0","article-title":"Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review","volume":"161","author":"Fernandes","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/atm.2020.01.76","article-title":"Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients","volume":"8","author":"Ma","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0026","doi-asserted-by":"crossref","first-page":"705","DOI":"10.21037\/atm-22-2619","article-title":"Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients","volume":"10","author":"Wei","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0027","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00520-011-1241-6","article-title":"Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy","volume":"20","author":"Chan","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0028","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21873\/anticanres.16156","article-title":"Clinical verification on the predictors for febrile neutropenia in breast cancer patients treated with neoadjuvant chemotherapy","volume":"43","author":"Goto","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0029","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1349-7006.2009.00992.x","article-title":"Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice","volume":"100","author":"Minami","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","article-title":"Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer","volume":"16","author":"Bruno","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0031","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ejca.2003.12.026","article-title":"Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy","volume":"40","author":"Rudek","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0032","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bcp.15526","article-title":"A pharmacometrics model to define docetaxel target in early breast cancer","volume":"89","author":"Aldaz","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.10.006_bib0033","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1200\/JCO.2002.01.025","article-title":"Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies","volume":"20","author":"Goh","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:57:18Z","timestamp":1736366238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0149291824002960"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.10.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated With Docetaxel-Based Chemotherapy: A Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}